Reading a case example critically
Quick answer
EHL Bio publishes a case example where glucose fell from 300 to 120 mg/dL and HbA1c (NGSP) from 10.8% to 6.3% after stem cell treatment. The numbers are striking but they are single-case data, not a randomised controlled trial. The scientific rationale is that MSCs reduce chronic inflammation and insulin resistance, rather than fully regenerating beta cells.
HbA1c reflects average glucose over about 2-3 months. A drop from 10.8% to 6.3% is clinically large, but changes of that size also occur through medication adjustment, diet and weight loss — factors case examples rarely separate out.
In type 2 diabetes, the plausible mechanism is reduced inflammation in adipose tissue and liver, improving insulin sensitivity. In type 1, where beta cells are destroyed by autoimmunity, research targets immune modulation and insulin-producing cell generation — a far harder problem.
What is proven far more clearly: 5-10% weight loss, combined aerobic and resistance exercise, and medications such as metformin, GLP-1 receptor agonists and SGLT2 inhibitors, which have solid data on reducing cardiac and renal complications.
If considering cell therapy, treat it as an add-on after the basics are controlled, and never reduce or stop diabetes medication on your own — the risk of acute hyperglycaemia is real.
Do not expect that. Medication changes must be made by a physician based on actual lab results.
Still early-stage research, since it must address both the autoimmunity destroying beta cells and the regeneration of insulin-producing cells.
HbA1c, renal function (eGFR, urine protein), eye exam, foot exam and lipid profile, to map existing complications.
Long-term data are weak, and without lifestyle change glucose typically drifts back up.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Diabetes & wounds